Citation Tools

Download PDFPDF
IDDF2024-ABS-0205 Impact of long-term treatment with continuous tenofovir alafenamide (TAF) or after switch from tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)

Download to a citation manager

Cite this article as:
Lim Y, Wong G, Ahn SH, et al
IDDF2024-ABS-0205 Impact of long-term treatment with continuous tenofovir alafenamide (TAF) or after switch from tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)